Do you know that most people work for 8 hours a day? Now imagine if an AI could do the same, without getting tired. That’s what Claude 4, the new AI from Anthropic, can do.
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
Shares of Wipro fell sharply, by about 4.4%, after its Q2 results failed to impress the market. The drop reflects deep concerns about growth, margins, and guidance. To make things tougher, Jefferies called the stock’s risk-reward ratio “unattractive. We see that investors are not just reacting to one quarter’s numbers. They are asking whether Wipro…
The Bitcoin Price recently dipped below $100,000, but it rebounded quickly, reclaiming $101,000, a sign of its surprising resilience amid rising Middle East tensions. Let’s have a look into what drove this movement and what might come next. Continue Reading on Meyka This article is available in full on our main platform. Get access to…
The Indian Renewable Energy Development Agency (IREDA) has reported remarkable growth in the first half (H1) of the financial year 2025. The agency witnessed an 86% surge in loan sanctions and a 54% increase in loan disbursements, underscoring the rising momentum of India’s renewable energy sector. Continue Reading on Meyka This article is available in…
The announcement that dozens of Priceline Pharmacy stores have entered administration has triggered widespread discussion about the future of community pharmacies and the sustainability of retail healthcare models. The Priceline pharmacy administration process involves stores previously operated by a major pharmacy group that was unable to continue meeting its financial commitments. While stores remain open…
Samsung is stealing the spotlight in global markets as its stock edges closer to an all-time high. Investors are rushing in, excited by the growing demand for artificial intelligence (AI) technology and a strong rebound in the semiconductor industry. On October 10, 2025, Samsung Electronics’ shares continued their upward trend, reflecting renewed confidence in its…
In a major development for the biotech industry and global health sector, Moderna has agreed to settle a long running COVID Vaccine patent dispute for up to $2.25 billion. The agreement closes a key legal battle linked to its blockbuster mRNA based COVID 19 vaccine, widely known as Spikevax. Continue Reading on Meyka This article…